Gastroenterologia y hepatologia最新文献_第6页

Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis. 溃疡性结肠炎患者美沙拉胺不耐受的新型脱敏治疗。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-09 DOI: 10.1016/j.gastrohep.2025.502347

Kenji Kinoshita, Shintaro Sawaguchi, Kai Toyoshima, Sonoe Yoshida, Takahiro Yamamura, Kosuke Nagai, Ikko Tanaka, Kazuteru Hatanaka, Yoshiya Yamamoto, Hirohito Naruse, Takehiko Katsurada, Naoya Sakamoto

{"title":"Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis.","authors":"Kenji Kinoshita, Shintaro Sawaguchi, Kai Toyoshima, Sonoe Yoshida, Takahiro Yamamura, Kosuke Nagai, Ikko Tanaka, Kazuteru Hatanaka, Yoshiya Yamamoto, Hirohito Naruse, Takehiko Katsurada, Naoya Sakamoto","doi":"10.1016/j.gastrohep.2025.502347","DOIUrl":"10.1016/j.gastrohep.2025.502347","url":null,"abstract":"<p><strong>Background: </strong>Mesalamine is the first-line drug for treating mild-to-moderate ulcerative colitis (UC); however, some patients develop symptoms of intolerance. Although several desensitization methods have been reported, these desensitization regimens were rather complicated for physicians to prescribe in daily clinical practice; therefore, it has not yet become a major therapeutic option for intolerance patients. Thus, we developed an alternative desensitization protocol.</p><p><strong>Methods: </strong>We performed a single-center, retrospective study of patients with UC, who were intolerant to mesalamine and had undergone desensitization therapy. Desensitization starts with 50mg of granule mesalamine, with an increase in the dose by 50mg every week up to 200mg, followed by incremental doses of 100mg every week. After patients received dosages of more than 1000mg, the dose was increased by 200mg every week up to the target dose. Concomitant medications such as oral prednisolone or budesonide rectal foam were allowed during the protocol but were withdrawn before the end of desensitization. We evaluated the success rate of our mesalamine desensitization method and performed safety assessments during the protocol.</p><p><strong>Results: </strong>Of 115 patients, 17 were intolerant to mesalamine. We excluded six patients who had severe disease or organ disorders. Overall, 11 patients received desensitization therapy without hospitalization. All 11 patients successfully underwent desensitization therapy and received the target dose of mesalamine (3000-4000mg/day) at the end of the protocol. No serious adverse events were observed during this protocol.</p><p><strong>Conclusions: </strong>This retrospective study reports a successful and safe desensitization method for UC patients with mesalamine intolerance.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502347"},"PeriodicalIF":2.2,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cricopharyngeal bar: A rare entity. 巴伐利亚：一个不寻常的实体。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-09 DOI: 10.1016/j.gastrohep.2025.502348

Jeronimo Toro-Calle, Daniel Herrera, Maria Alejandra Mesa

引用次数: 0

Cost analysis of hidden hepatitis D virus infection in Spain. 西班牙隐性丁型肝炎病毒感染成本分析。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-08 DOI: 10.1016/j.gastrohep.2025.502337

Xavier Forns, Manuel Rodríguez, Raquel Domínguez-Hernández, Helena Cantero, Laura Salinas-Ortega, Miguel Ángel Casado

{"title":"Cost analysis of hidden hepatitis D virus infection in Spain.","authors":"Xavier Forns, Manuel Rodríguez, Raquel Domínguez-Hernández, Helena Cantero, Laura Salinas-Ortega, Miguel Ángel Casado","doi":"10.1016/j.gastrohep.2025.502337","DOIUrl":"10.1016/j.gastrohep.2025.502337","url":null,"abstract":"<p><strong>Introduction: </strong>A significant percentage of patients coinfected with hepatitis B virus (HBV) and hepatitis D virus (HDV) are undiagnosed. Coinfected patients progress to advanced liver disease faster than HBV monoinfected patients, thereby consuming more healthcare resources. The aim was to perform an analysis to determine the cost of hidden HDV infection in Spain.</p><p><strong>Methods: </strong>An analytical model was developed to estimate the prevalence of hidden HDV infection with/without advanced liver disease at the time of diagnosis. An epidemiological flow chart was established to quantify undiagnosed chronic hepatitis D patients. The percentages of patients with compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) and requiring liver transplantation (LT) and their annual costs were subsequently obtained from the literature. Direct healthcare costs were considered within a time horizon of 1 year. For patients without advanced disease, the consumption of healthcare resources was obtained from an experts panel.</p><p><strong>Results: </strong>A total of 2180 patients with hidden HDV infection were estimated; of these, 1188 (54%) had advanced liver disease (29%-CC, 57%-DC, and 8%-HCC) or underwent LT (6%), and 992 (46%) patients did not have advanced disease. The total annual cost of hidden HDV would be € 17.8million (€ 16.9million with advanced disease and € 882,400 for those without).</p><p><strong>Conclusions: </strong>Hidden HDV infection represents a high economic burden in Spain due to the rapid progression of liver disease in affected patients. These results highlight the importance of early diagnosis to prevent future clinical and economic burden related to liver disease progression.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502337"},"PeriodicalIF":2.2,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142964501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of renal replacement therapy in improving normothermic machine perfusion of liver grafts

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-04 DOI: 10.1016/j.gastrohep.2025.502336

Jordi Vengohechea, Aida Vaquero-Rey, Constantino Fondevila, Amelia J. Hessheimer

引用次数: 0

Fenómenos tromboembólicos en la enfermedad inflamatoria intestinal y riesgo con tratamientos JAK 炎症性肠病中的血栓栓塞现象及 JAK 治疗的风险。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-01 DOI: 10.1016/j.gastrohep.2024.502257

José Luis Rueda García , José Manuel Benitez , Iria Baston Rey , Margalida Calafat Sard , Cristina Suárez Ferrer

引用次数: 0

Tratamiento de la hipertrigliceridemia grave mediante recambio plasmático terapéutico en pacientes con pancreatitis aguda o en riesgo de padecerla 通过治疗性血浆置换，治疗急性胰腺炎患者或有患急性胰腺炎风险的患者的严重高甘油三酯血症。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-01 DOI: 10.1016/j.gastrohep.2024.502229

Eva Marín-Serrano , Ana Kerguelen Fuentes , Rubén Fernández-Martos , José Mostaza Prieto , Aurora Viejo Llorente , Ana Barbado Cano , Pedro Luis Martínez Hernández , María Dolores Martín-Arranz

{"title":"Tratamiento de la hipertrigliceridemia grave mediante recambio plasmático terapéutico en pacientes con pancreatitis aguda o en riesgo de padecerla","authors":"Eva Marín-Serrano , Ana Kerguelen Fuentes , Rubén Fernández-Martos , José Mostaza Prieto , Aurora Viejo Llorente , Ana Barbado Cano , Pedro Luis Martínez Hernández , María Dolores Martín-Arranz","doi":"10.1016/j.gastrohep.2024.502229","DOIUrl":"10.1016/j.gastrohep.2024.502229","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>TPE drastically reduces serum triglyceride (sTG), but its role in the treatment of hypertriglyceridemia-induced acute pancreatitis (HTG-AP) or at risk of developing it, is not well established. The objectives were to assess the effectiveness and safety of TPE in the treatment of severe HTG (sHTG), as well as to evaluate the severity of HTG-AP treated with TPE.</div></div><div><h3>Materials and methods</h3><div>Observational-retrospective-single-center study, in which a descriptive analysis of sHTG treated with TPE was conducted, with the aim of treating HTG-AP or preventing its recurrence. TPE was performed if sTG≥ 1000 mg/dL after 24 hours of admission.</div></div><div><h3>Results</h3><div>42 TPE were performed to treat 35 sHTG in 23 patients: 29 HTG-AP, and 6 sHTG with previous HTG-AP. Among the patients, 37% (13/55) were women, with 37 ± 14 years-old, 74.3% had normal BMI (25/35), 34% (12/35) were drinking > 40 g/alcohol/day and 54% (19/35) were diabetics. TPE significantly reduced the baseline sTG (4425 ± 2782 mg/dL vs. 709 ± 353 mg/dL, p < 0.001) in a single session, achieving a mean percentage reduction of 79 ± 13%; 20% (7/35) of sHTG cases required two TPE sessions to reduce sTG to < 1000 mg/dL. Adverse effects were reported in 4/42 TPE sessions (9,5%). sHTG-AP was observed in 3% of cases (1/29), and there were no deaths. sTG at 24 hours of admission showed no relation with the severity of APs.</div></div><div><h3>Conclusion</h3><div>The treatment of sHTG with TPE, with the aim of treating HTG-AP or preventing its recurrence, reduces sTG quickly and safety.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 1","pages":"Article 502229"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy 克罗恩病患者动脉僵化加剧：发病率、相关因素和抗肿瘤坏死因子疗法的影响。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-01 DOI: 10.1016/j.gastrohep.2024.502252

Mahrez Fissah , Adel Rechach , Meriem Charifi , Farouk Menzou , Said Taharboucht , Messaouda Djouhri , Leila Talbi , Nadia Touati , Lamine Atif , Mehdi Rabhia , Ahcene Chibane

{"title":"Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy","authors":"Mahrez Fissah , Adel Rechach , Meriem Charifi , Farouk Menzou , Said Taharboucht , Messaouda Djouhri , Leila Talbi , Nadia Touati , Lamine Atif , Mehdi Rabhia , Ahcene Chibane","doi":"10.1016/j.gastrohep.2024.502252","DOIUrl":"10.1016/j.gastrohep.2024.502252","url":null,"abstract":"<div><h3>Introduction</h3><div>Recent studies have demonstrated the growing interest in cardiovascular risk in Crohn's disease (CD), the aim of our work is to highlight the need for research into the frequency of arterial stiffness (AS) and its link with certain associated factors, particularly those related to inflammation.</div></div><div><h3>Materials and methods</h3><div>This was a cross-sectional observational study involving 118 patients with CD. Pulse wave velocity (PWV) measured by applanation tonometry was the criterion for calculating AS, the study also investigated the association of AS especially the indicators of inflammation, as well as the impact of anti-TNF alpha therapy on AS.</div></div><div><h3>Results</h3><div>The prevalence of AS, after adjustment for age and blood pressure level reached more than a quarter of patients compared to the cardiovascular risk which was low. The factors that were strongly associated with AS were age, systolic and diastolic blood pressure. Two parameters related to inflammation emerged as having a highly significant link after multivariate analysis: recurrence in the last year and length of disease with a <em>p</em>  <!-->0.008, and an OR of 5 and 9 successively. Patients treated with anti-TNF alpha had a significant reduction in PWV.</div></div><div><h3>Conclusion</h3><div>The prevalence of AS reached more than a quarter of patients with CD, the duration and recurrence rate of CD appear to be factors linked to inflammation. Treatment with anti-TNF alpha seems to slow down PWV in these patients.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 1","pages":"Article 502252"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastric antral ectasia and diaphragmatic hernia: A rare cause of iron deficiency anemia 胃前庭异位症和膈疝：缺铁性贫血的罕见病因。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-01 DOI: 10.1016/j.gastrohep.2024.502209

Ana Lancho Muñoz, Patricia Abellán Alfocea, Eduardo Redondo Cerezo

引用次数: 0

Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain) 人工智能辅助识别和检索庞特韦德拉和奥萨尔内斯卫生区（西班牙）失去随访的慢性丙型肝炎患者。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-01 DOI: 10.1016/j.gastrohep.2024.502226

Pablo Parada Vázquez , Santiago Pérez-Cachafeiro , Belén Castiñeira Domínguez , Juan Manuel González-Pérez , José Manuel Mera Calviño , Raquel Souto-Rodríguez , Yolanda Falagán Cachafeiro , Indhira Pérez-Medrano , Nuria Vázquez-Temprano , Matilde Trigo , Alba Carrodeguas , José Luis González-Sánchez , Carmen Durán-Parrondo , Juan Turnes

{"title":"Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain)","authors":"Pablo Parada Vázquez , Santiago Pérez-Cachafeiro , Belén Castiñeira Domínguez , Juan Manuel González-Pérez , José Manuel Mera Calviño , Raquel Souto-Rodríguez , Yolanda Falagán Cachafeiro , Indhira Pérez-Medrano , Nuria Vázquez-Temprano , Matilde Trigo , Alba Carrodeguas , José Luis González-Sánchez , Carmen Durán-Parrondo , Juan Turnes","doi":"10.1016/j.gastrohep.2024.502226","DOIUrl":"10.1016/j.gastrohep.2024.502226","url":null,"abstract":"<div><h3>Objective</h3><div>Direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection offer an opportunity to eliminate the disease. This study aimed to identify and relink to care HCV patients previously lost to medical follow-up in the health area of Pontevedra and O Salnés (Spain) using an artificial intelligence-assisted system.</div></div><div><h3>Patients and methods</h3><div>Active retrospective search of previously diagnosed HCV cases recorded in the Galician Health Service proprietary health information exchange database using the Herramientas para la EXplotación de la INformación (HEXIN) application.</div></div><div><h3>Results and conclusions</h3><div>Out of 99 lost patients identified, 64 (64.6%) were retrieved. Of these, 62 (96.88%) initiated DAA treatment and 54 patients (87.1%) achieved a sustained virological response. Mean time from HCV diagnosis was over 10 years. Main reasons for loss to follow-up were fear of possible adverse effects of treatment (30%) and mobility impediments (21%). Among the retrieved patients, almost one in three presented advanced liver fibrosis (F3) or cirrhosis (F4) at evaluation. In sum, HCV patients lost to follow-up can be retrieved by screening past laboratory records. This strategy promotes the achievement of HCV elimination goals.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 1","pages":"Article 502226"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Síndrome de heterotaxia: cuando casi nada es como debería ser 异位综合征：当几乎所有事情都不尽如人意时。

IF 2.2 4区医学

Gastroenterologia y hepatologia Pub Date : 2025-01-01 DOI: 10.1016/j.gastrohep.2024.502233

Luisa Adán-Merino , Francisco Garrido Gallego , Rodrigo Pastorín-Salis , Ángel Ponferrada-Díaz

引用次数: 0